Comerica Bank acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,708 shares of the biotechnology company’s stock, valued at approximately $242,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. QS Investors LLC increased its position in shares of bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares in the last quarter. World Asset Management Inc bought a new stake in shares of bluebird bio in the 3rd quarter valued at $230,000. Bank of Montreal Can increased its position in shares of bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC bought a new stake in shares of bluebird bio in the 2nd quarter valued at $184,000. Finally, SG Americas Securities LLC increased its position in shares of bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares in the last quarter.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at $159.40 on Thursday. bluebird bio, Inc. has a fifty-two week low of $60.95 and a fifty-two week high of $174.65.
A number of analysts recently commented on the stock. BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Morgan Stanley restated a “hold” rating on shares of bluebird bio in a research report on Wednesday, August 9th. Leerink Swann restated an “outperform” rating and issued a $120.00 price objective on shares of bluebird bio in a research report on Saturday, September 30th. Jefferies Group reaffirmed a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday, August 11th. Finally, Canaccord Genuity assumed coverage on shares of bluebird bio in a research note on Tuesday. They issued a “buy” rating and a $202.00 target price for the company. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $137.57.
In other news, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $125.73, for a total value of $616,077.00. Following the sale, the insider now directly owns 32,205 shares of the company’s stock, valued at approximately $4,049,134.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the sale, the chief operating officer now directly owns 13,718 shares in the company, valued at $2,361,553.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,450 shares of company stock worth $15,790,373. 3.90% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Comerica Bank Takes Position in bluebird bio, Inc. (BLUE)” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/07/comerica-bank-takes-position-in-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.